Identification of an Agent Selectively Targeting DPC4 (Deleted in Pancreatic Cancer Locus 4)–Deficient Pancreatic Cancer Cells
The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
One of the most common types of genetic alterations in cancer is the loss-of-function mutations in tumor-suppressor genes. Such mutations are usually very specific to cancer cells and present attractive and unique opportunities for therapeutic interventions. However, for various reasons, antitumor agents that target loss-of-function mutations have not been readily identified. In this report, using the deleted in pancreatic cancer locus 4 (DPC4) gene in pancreatic cancer as an example, we show the feasibility of a novel screening strategy, which we have named Pharmacological Synthetic Lethal Screening, for the identification of agents that selectively target cancer cells with loss-of-function mutations. We created DPC4 isogenic cell lines through the restoration of wild-type DPC4 in a pancreatic cancer cell line, BxPC-3, whose DPC4 gene was homozygously deleted. The isogenic cell lines were then used in the Pharmacological Synthetic Lethal Screening to evaluate compound libraries for antiproliferative activity and selectivity against DPC4 deficiency. After screening 19,590 compounds, we identified one lead compound, UA62001, which showed 4.6-fold selectivity against DPC4 deficiency in the DPC4 isogenic cell lines. UA62001 selectivity was also seen in another set of DPC4 isogenic cell lines generated by small interfering RNA knockdown. In addition, UA62001 was evaluated in commonly used pancreatic cancer cell lines. A fairly good correlation between DPC4 deficiency and UA62001 sensitivity was observed. Cell cycle analysis indicates that UA62001 arrests cells in S and G2-M phases. The results of microarray gene expression profiling and quantitative real-time reverse transcription-PCR suggest that cyclin B/CDC2 and minichromosome maintenance complexes might be the downstream cellular targets of UA62001. (Cancer Res 2006; 66(19): 9722-30)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Boyd, M. R., & Paull, K. D. (1995) · Drug Development Research · doi:10.1002/ddr.430340203 · Cited by 1,572
Dolma, S., Lessnick, S. L., Hahn, W. C., & Stockwell, B. R. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00050-3 · Cited by 1,446
Genetic profile of 22 pancreatic carcinoma cell lines: Analysis of K-ras, p53, p16 and DPC4/Smad4
Moore, P. S., Sipos, B., Orlandini, S., Sorio, C., Real, F. X., Lemoine, N. R., Gress, T., Bassi, C., Klöppel, G., Kalthoff, H., et al. (2001) · Virchows Archiv · doi:10.1007/s004280100474 · Cited by 329
Role of Smad4 (DPC4) inactivation in human cancer
Miyaki, M., & Kuroki, T. (2003) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(03)01066-0 · Cited by 242
Heinmöller, E., Dietmaier, W., Zirngibl, H., Heinmöller, P., Scaringe, W., Jauch, K.-W., Hofstädter, F., & Rüschoff, J. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64520-8 · Cited by 121
Cited by
Maitra, A., & Hruban, R. H. (2008) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev.pathmechdis.3.121806.154305 · Cited by 707
The role of TGF-β/SMAD4 signaling in cancer
Zhao, M., Mishra, L., & Deng, C.-X. (2018) · International Journal of Biological Sciences · doi:10.7150/ijbs.23230 · Cited by 631
“Although limited knowledge is availabale regarding the mechanism, some molecules associated to SMAD4, including UA62001 and UA62784, have been developed as candidates in cancer treatment [71, 117].”
BackgroundHu, H.-F., Ye, Z., Qin, Y., Xu, X.-W., Yu, X.-J., Zhuo, Q.-F., & Ji, S.-R. (2021) · Acta Pharmacologica Sinica · doi:10.1038/s41401-020-00584-2 · Cited by 149
SMAD4 and the TGFβ Pathway in Patients with Pancreatic Ductal Adenocarcinoma
Dardare, J., Witz, A., Merlin, J.-L., Gilson, P., & Harlé, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21103534 · Cited by 101
“In SMAD4-negative pancreatic cancer cells treated with the compound UA62001, the cell cycle was interrupted in synthesis (S) and Gap 2 (G2) – mitotic (M) phases [74], whereas UA62784 activated CDK1 and induced mitotic cell-cycle arrest and apoptosis [75].”
Background
Metadata
- Authors
- Wang, H., Han, H., & Von Hoff, D. D.
- Venue
- Cancer Research
- Published
- 2006-10-01
- Volume
- 66
- Issue
- 19
- Pages
- 9722-9730
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- OpenAlex
- W2012841672
- Cited by
- 73
- References
- 5
- FWCI
- 1.71
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Identification of an Agent Selectively Targeting DPC4 (Deleted in Pancreatic Cancer Locus 4)–Deficient Pancreatic Cancer Cells. https://app.cochat.ai/papers/10.1158/0008-5472.can-05-4602
- The paper
- Wang, H., Han, H., & Von Hoff, D. D. (2006). Identification of an Agent Selectively Targeting DPC4 (Deleted in Pancreatic Cancer Locus 4)–Deficient Pancreatic Cancer Cells. Cancer Research. https://doi.org/10.1158/0008-5472.can-05-4602
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.